{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bunin DI"],"funding":["HHS","NICHD NIH HHS","U.S. Department of Health and Human Services","National Institutes of Health (NIH)","Oregon National Primate Research Center, Oregon Health & Science University","NIH HHS","Division of Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)"],"pagination":["1919-1934"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12145459"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(7)"],"pubmed_abstract":["<h4>Background</h4>Dimethandrolone undecanoate (DMAU) is under development as a single agent hormonal male contraceptive. DMAU is a prodrug hydrolyzed by esterase(s) to the active metabolite dimethandrolone (DMA) which has dual androgenic and progestogenic actions. Phase 1 clinical trial results show DMAU to be well-tolerated as an oral contraceptive in healthy men; however, delivery of DMAU as a long-acting injectable rather than a daily oral formulation would provide user compliance benefits and address oral bioavailability concerns.<h4>Objective</h4>To assess the safety, pharmacokinetics (PK), and long-acting contraceptive potential of DMAU in male non-human primates (NHP) when delivered as an injectable or oral formulation.<h4>Materials and methods</h4>DMAU was administered to cynomolg"],"journal":["Andrology"],"pubmed_title":["Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive."],"pmcid":["PMC12145459"],"funding_grant_id":["P51OD011092","HHSN275201500002C","HHSN275201500002I","P51 OD011092","75N94020D00003"],"pubmed_authors":["Bunin DI","Adevai T","Gahagen J","Zelinski MB","Tang L","Iyer L","Lee MS","Wang C","Kim K","Endsley A","Parman T","Blithe DL"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive.","description":"<h4>Background</h4>Dimethandrolone undecanoate (DMAU) is under development as a single agent hormonal male contraceptive. DMAU is a prodrug hydrolyzed by esterase(s) to the active metabolite dimethandrolone (DMA) which has dual androgenic and progestogenic actions. Phase 1 clinical trial results show DMAU to be well-tolerated as an oral contraceptive in healthy men; however, delivery of DMAU as a long-acting injectable rather than a daily oral formulation would provide user compliance benefits and address oral bioavailability concerns.<h4>Objective</h4>To assess the safety, pharmacokinetics (PK), and long-acting contraceptive potential of DMAU in male non-human primates (NHP) when delivered as an injectable or oral formulation.<h4>Materials and methods</h4>DMAU was administered to cynomolg","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-07-15T12:33:54.721Z","creation":"2026-07-04T03:13:00.967Z"},"accession":"S-EPMC12145459","cross_references":{"pubmed":["39648590"],"doi":["10.1111/andr.13819"]}}